Ameriprise
BCAX

Ameriprise’s Bicara Therapeutics BCAX Stock Holding History

Ameriprise’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.57M Buy
288,749
+272,931
+1,725% +$6.09M ﹤0.01% 2158
2026
Q1 		$315K Sell
15,818
-214
-1% -$3.68K ﹤0.01% 3743
2025
Q4 		$270K Buy
16,032
+50
+0.3% +$854 ﹤0.01% 3834
2025
Q3 		$252K Sell
15,982
-108
-0.7% -$1.21K ﹤0.01% 3843
2025
Q2 		$149K Buy
+16,090
New +$192K ﹤0.01% 3850
2024
Q4 		– Sell
-200,000
Closed -$5.09M – 4172
2024
Q3 		$5.09M Buy
+200,000
New +$5.1M ﹤0.01% 2363

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise's BCAX Position: Q2 2026 in Review

Ameriprise increased its Bicara Therapeutics (BCAX) stake by 1,725% in Q2 2026, buying an estimated $6.09M and bringing the position to 288,749 shares worth $8.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2158.

Ameriprise first reported a position in BCAX in Q3 2024 and has held it in 6 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Ameriprise held 288,749 shares of Bicara Therapeutics worth $8.57M as of Q2 2026.
  • Ameriprise bought 272,931 Bicara Therapeutics shares in Q2 2026, an estimated $6.09M.
  • Bicara Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2158 holding.
  • Ameriprise first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.